Pomalyst vs Repatha
Side-by-side drug price comparison from Medicare Part D data
Verdict
Repatha costs 96% less per claim than Pomalyst ($757.00 vs $17250.00). Neither drug has a generic alternative available. Total Medicare spending: Pomalyst at $3.3B vs Repatha at $2.6B.
| Metric | Pomalyst | Repatha |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $17,250 | $757* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $3.3B | $2.6B |
| Total Claims | 192,000 | 3,420,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 4.7%* | 24.6% |
| Generic Available | No | No |
| Condition | Cancer | High Cholesterol |
| Total Beneficiaries | 18,000 | 398,000 |
Repatha costs 96% less per claim than Pomalyst ($757.00 vs $17250.00). Neither drug has a generic alternative available. Total Medicare spending: Pomalyst at $3.3B vs Repatha at $2.6B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both entity A and entity B. What follows is the interpretation — which specific axes carry the most weight for entity A versus entity B, and which differences are large enough to influence a real decision.
Practical use of the comparison: read the data above, then drill into the individual entity A and entity B detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.